Exploratory endpoints assessed over a 24-month follow-up include the enumeration of CTCs and the characterization of molecular alterations in both liquid biopsy markers and tumor tissue samples collected after PSMA-RLT, post-surgery, and during follow-up. The gene discussed is FOLH1; the disease is neoplasm.